EGFR and non-small cell lung carcinoma: Despite the significantly higher prevalence of EGFR mutations in female non-smokers and in patients with women-predominant non-small cell lung cancer (NSCLC), it has been suggested that restricting screenings to only never-smoking women would overlook 57% of all EGFR mutations.